The patent expiry of all four existing EMEA approved drugs for Alzheimer's disease (AD) by 2015 is likely to cause a steep decline in the growth of the European AD medication market. However, the approval of next generation therapies that can delay disease progression and restore cognitive functions are expected to revive opportunities in the market from 2015 to 2018.
Catalent Pharma Solutions today announced the launch of its Catalent Applied Drug Delivery Institute at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Chicago, IL.
New benchmarking data reveal that medical device companies' compliance team budgets dropped by an average 24 percent in 2012, said Cutting Edge Information.
According to a release, pharmaceutical compliance team budgets remained relatively flat between 2010 and this year, according to a new study by the benchmarking firm.
Orphan drugs treat rare diseases, affecting from 1 to 200,000 people - they are the new blockbusters according to analysis done by Life Sciences consultants with Thomson Reuters. The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today released the results of its study on orphan drugs, developed to treat rare diseases, finding that they have the potential to generate as much lifetime revenue as drugs used for more common health conditions.
GBI Research, leading business intelligence provider, has released its latest research report, entitled "Pharmaceutical Supply Chain in Europe - Adoption of Direct to Pharmacy (DTP) Model to Boost Efficiency and Optimize Pricing". The report focuses on the current scenario of supply chain management. Key participants in the pharmaceutical supply chain in Europe are covered in the report as well as issues such as pricing, labeling, packaging, warehousing, logistics, and distribution.
Health spending in May 2012 grew by a modest 3.8 percent compared to May 2011, continuing a trend of roughly 4 percent annual growth since 2009. Health care prices in May 2012 were 2.0 percent higher than in May 2011, ticking up a tenth from April. On a 12-month moving average basis, price growth is lower now than at any time since January 1999.
These data come from the July Health Sector Economic Indicators briefs released by Altarum Institute’s Center for Sustainable Health Spending.